These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16737872)

  • 21. Meeting report: the use of newborn blood spots in environmental research: opportunities and challenges.
    Olshan AF
    Environ Health Perspect; 2007 Dec; 115(12):1767-79. PubMed ID: 18087597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Data integration and warehousing: coordination between newborn screening and related public health programs.
    Therrell BL
    Southeast Asian J Trop Med Public Health; 2003; 34 Suppl 3():63-8. PubMed ID: 15906697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Committee report: Considerations and recommendations for national guidance regarding the retention and use of residual dried blood spot specimens after newborn screening.
    Therrell BL; Hannon WH; Bailey DB; Goldman EB; Monaco J; Norgaard-Pedersen B; Terry SF; Johnson A; Howell RR
    Genet Med; 2011 Jul; 13(7):621-4. PubMed ID: 21602691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I.
    Magera MJ; Gunawardena ND; Hahn SH; Tortorelli S; Mitchell GA; Goodman SI; Rinaldo P; Matern D
    Mol Genet Metab; 2006 May; 88(1):16-21. PubMed ID: 16448836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Informing parents about newborn screening.
    Kemper AR; Fant KE; Clark SJ
    Public Health Nurs; 2005; 22(4):332-8. PubMed ID: 16150014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of sex-specific gene expression in archived dried blood spots (DBS).
    Resau JH; Ho NT; Dykema K; Faber MS; Busik JV; Nickolov RZ; Furge KA; Paneth N; Jewell S; Khoo SK
    Int J Mol Sci; 2012; 13(8):9599-9608. PubMed ID: 22949818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. National evaluation of US newborn screening system components.
    Therrell BL; Hannon WH
    Ment Retard Dev Disabil Res Rev; 2006; 12(4):236-45. PubMed ID: 17183567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Newborn screening residual dried blood spot use for newborn screening quality improvement.
    Benkendorf J; Goodspeed T; Watson MS
    Genet Med; 2010 Dec; 12(12 Suppl):S269-72. PubMed ID: 21150375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proficiency testing outcomes of 3-hydroxyisovalerylcarnitine measurements by tandem mass spectrometry in newborn screening.
    Lim TH; De Jesús VR; Meredith NK; Sternberg MR; Chace DH; Mei JV; Hannon WH
    Clin Chim Acta; 2011 Mar; 412(7-8):631-5. PubMed ID: 21185274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Status of newborn screening programs in the United States.
    Therrell BL; Johnson A; Williams D
    Pediatrics; 2006 May; 117(5 Pt 2):S212-52. PubMed ID: 16735250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Newborn screening in Australia and New Zealand.
    Webster D; ;
    Southeast Asian J Trop Med Public Health; 2003; 34 Suppl 3():69-70. PubMed ID: 15906698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Common criteria among States for storage and use of dried blood spot specimens after newborn screening.
    Petrini C; Olivieri A; Corbetta C; Cerone R; D'Agnolo G; Bompiani A
    Ann Ist Super Sanita; 2012; 48(2):119-21. PubMed ID: 22751553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Completeness and complexity of information available to parents from newborn-screening programs.
    Fant KE; Clark SJ; Kemper AR
    Pediatrics; 2005 May; 115(5):1268-72. PubMed ID: 15867034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance.
    Bertagnolio S; Parkin NT; Jordan M; Brooks J; García-Lerma JG
    AIDS Rev; 2010; 12(4):195-208. PubMed ID: 21179184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Governing biological material at the intersection of care and research: the use of dried blood spots for biobanking.
    Douglas CM; van El CG; Faulkner A; Cornel MC
    Croat Med J; 2012 Aug; 53(4):390-7. PubMed ID: 22911534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of DNA extraction methods for dried blood spots in the diagnosis of congenital cytomegalovirus infection.
    de Vries JJ; Claas EC; Kroes AC; Vossen AC
    J Clin Virol; 2009 Dec; 46 Suppl 4():S37-42. PubMed ID: 19781984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Newborn screening: a literature review.
    Kayton A
    Neonatal Netw; 2007; 26(2):85-95. PubMed ID: 17402600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ethical, legal and social issues in newborn screening in the United States.
    Therrell BL
    Southeast Asian J Trop Med Public Health; 2003; 34 Suppl 3():52-8. PubMed ID: 15906695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Public support for the use of newborn screening dried blood spots in health research.
    Duquette D; Rafferty AP; Fussman C; Gehring J; Meyer S; Bach J
    Public Health Genomics; 2011; 14(3):143-52. PubMed ID: 21178324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up data collection and use in state newborn screening programs.
    Hoff T; Ayoob M; Therrell BL
    Arch Pediatr Adolesc Med; 2007 Oct; 161(10):994-1000. PubMed ID: 17909144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.